摘要
目的:分析加减参苓白术散联合FOLFOX4方案化疗治疗晚期胃癌的临床疗效。方法:选取2017年1月-2019年1月在我院接受治疗的82例晚期胃癌患者,按照随机数字表法将患者分为两组,各41例。对照组给予FOLFOX4方案化疗,观察组在对照组化疗基础上联合参苓白术汤加减治疗。对比两组临床疗效、治疗前后生活质量评分、炎症免疫细胞水平、肿瘤标志物及不良反应发生情况。结果:相较于对照组,观察组治疗总有效率、治疗后生活质量评分、γ-干扰素(γ-Interferon, IFN-γ)水平均较高,不良反应发生率、各中医证候积分、肿瘤坏死因子-α(Tumor Necrosis Factor,TNF-α)水平、癌胚抗原(CarcinoEmbryonic Antigen,CEA)及糖类抗原19-9(CA19-9)水平均较低,差异有统计学意义(P <0.05)。结论:加减参苓白术散联合FOLFOX4方案化疗治疗晚期胃癌可取得明显的临床疗效,有效改善了临床症状,减轻炎症细胞反应,提高免疫功能,降低肿瘤标志物水平,对减少化疗不良反应、促进患者生活质量的提高具有重要的作用。
Objective: To analyze the clinical efficacy of Shenling Baizhu San( 参苓白术散) plus FOLFOX4 on advanced gastric cancer. Methods: 82 patients were divided into two groups, 41 cases in each. The control group was given FOLFOX4, and the observation group was treated with Shenling Baizhu San more. Results: The total efficiency, the quality of life score and IFN-γ were higher in the observation group. Adverse reactions, the scores of various TCM syndromes, TNF-α, CEA and CA19-9 were lower than the control group(P<0.05). Conclusion: Shenling Baizhu San plus FOLFOX4 on advanced gastric cancer was effective, by effectively improving clinical symptoms, reducing inflammatory cell response, improving immune function, reducing tumor marker levels and chemotherapy dysfunction.
出处
《中医临床研究》
2019年第31期84-86,共3页
Clinical Journal Of Chinese Medicine
